Dr. Eric Mao, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 195
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Warren Alpert Medical School of Brown University
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
CA license A147641 (first issued 2017; current) · RI license MD14655
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sutter Medical Center, Sacramento Sacramento, CA
- University of California Davis Medical Center Sacramento, CA
Medical groups
- Regents of the Univ of Ca (1,584 clinicians)
- Regents of the University of California (567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 195
- Services billed
- 410
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 91 | 82 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 85 | 84 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | 64 |
| Biopsy of large bowel using a flexible endoscope | 47 | 47 |
| New patient office or other outpatient visit, 60-74 minutes | 43 | 43 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 37 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 125 |
| Rinvoq (upadacitinib) | 67 |
| Skyrizi On-Body (risankizumab-rzaa) | 50 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Sacramento, CA | 46 |
| Mesalamine Other prescribers in Sacramento, CA | 46 |
| Humira Pen (adalimumab) Other prescribers in Sacramento, CA | 43 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Sacramento, CA | 39 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Sacramento, CA | 30 |
| Methotrexate (methotrexate sodium) Other prescribers in Sacramento, CA | 21 |
| Lactated Ringers (ringer's solution,lactated) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $112 in total to this clinician.
| Janssen Scientific Affairs, LLC | $112 |
|---|
| Food and Beverage | $112 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $188,492 in research payments for these studies, mostly to the institutions running them.
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie Inc. · Recruiting · NCT06548542 - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP)
AbbVie Inc. - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)
AbbVie Inc. - Mirikizumab LY3074828 pro uc cd - omvoh - ulcerative colitis
Eli Lilly and Company - An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Celgene Corporation · Terminated · NCT03467958
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.